% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Murad:180126,
      author       = {S. Murad and S. Michen and A. Becker and M. Füssel and G.
                      Schackert and T. Tonn and F. Momburg$^*$ and A. Temme},
      title        = {{NKG}2{C}+ {NK} {C}ells for {I}mmunotherapy of
                      {G}lioblastoma {M}ultiforme.},
      journal      = {International journal of molecular sciences},
      volume       = {23},
      number       = {10},
      issn         = {1422-0067},
      address      = {Basel},
      publisher    = {Molecular Diversity Preservation International},
      reportid     = {DKFZ-2022-01119},
      pages        = {5857},
      year         = {2022},
      abstract     = {In glioblastoma, non-classical human leucocyte antigen E
                      (HLA-E) and HLA-G are frequently overexpressed. HLA-E loaded
                      with peptides derived from HLA class I and from HLA-G
                      contributes to inhibition of natural killer (NK) cells with
                      expression of the inhibitory receptor CD94/NKG2A. We
                      investigated whether NK cells expressing the activating
                      CD94/NKG2C receptor counterpart were able to exert
                      anti-glioma effects. NKG2C+ subsets were preferentially
                      expanded by a feeder cell line engineered to express an
                      artificial disulfide-stabilized trimeric HLA-E ligand
                      (HLA-E*spG). NK cells expanded by a feeder cell line, which
                      facilitates outgrowth of conventional NKG2A+, and fresh NK
                      cells, were included for comparison. Expansion via the
                      HLA-E*spG feeder cells selectively increased the fraction of
                      NKG2C+ NK cells, which displayed a higher frequency of
                      KIR2DL2/L3/S2 and CD16 when compared to expanded NKG2A+ NK
                      cells. NKG2C+ NK cells exhibited increased cytotoxicity
                      against K562 and KIR:HLA-matched and -mismatched primary
                      glioblastoma multiforme (GBM) cells when compared to NKG2A+
                      NK cells and corresponding fresh NK cells. Cytotoxic
                      responses of NKG2C+ NK cells were even more pronounced when
                      utilizing target cells engineered with HLA-E*spG. These
                      findings support the notion that NKG2C+ NK cells have
                      potential therapeutic value for treating gliomas.},
      keywords     = {HLA-E (Other) / HLA-G (Other) / NK cells (Other) / brain
                      cancer (Other) / glioblastoma (Other) / immunotherapy
                      (Other)},
      cin          = {D121 / D120},
      ddc          = {540},
      cid          = {I:(DE-He78)D121-20160331 / I:(DE-He78)D120-20160331},
      pnm          = {314 - Immunologie und Krebs (POF4-314)},
      pid          = {G:(DE-HGF)POF4-314},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:35628668},
      doi          = {10.3390/ijms23105857},
      url          = {https://inrepo02.dkfz.de/record/180126},
}